Search This Blog

Monday, May 11, 2026

Galectin Phase 2b data show belapectin significantly reduced esophageal varice in MASH cirrhosi

 

Galectin Therapeutics: Hepatology NAVIGATE Phase 2b data show belapectin significantly reduced esophageal varice development in per‑protocol MASH cirrhosis patients

  • Peer‑reviewed Hepatology publication reports belapectin showed a favorable safety profile in the NAVIGATE Phase 2b MASH cirrhosis population.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)